- $3.57bn
- $3.08bn
- $517.15m
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Veracyte Inc reports results for the quarter ended June 30 - Earnings Summary
Veracyte Q2 revenue rises on Decipher and Afirma test sales
Brief: Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million
Brief: Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Brief: Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer
Veracyte Q1 revenue rises 21%, beats analyst estimates
Brief: Veracyte Q1 Revenue USD 139.1 Million Vs. IBES Estimate USD 130 Million
Brief: Veracyte Names Kevin Haas As Chief Development And Technology Officer
Veracyte Q4 revenue rises 19%, beats expectations
Brief: Veracyte Outlook FY Revenue Growth 16%
Genomic diagnostics firm Veracyte Q3 revenue beats estimates on higher testings
Brief: Veracyte Q3 Revenue USD 131.9 Million Vs. IBES Estimate USD 124.6 Million
Veracyte Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Veracyte Q2 Revenue USD 130.2 Million Vs. IBES Estimate USD 120.7 Million